Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Filippo de Marinis"'
Autor:
Paolo Bidoli, Daniele Turci, Hector Soto Parra, Domenico Galetta, Fabiana Vitiello, Teresa Gamucci, Paola Antonelli, Filippo de Marinis, Giuseppe Lo Russo, Angelo Delmonte, Enrico Cortesi, Francesco Grossi, Luana Calabrò, Andrea Ardizzoni, Alessandro Morabito, Diana Giannarelli, Antonio Chella, Federico Cappuzzo, Lucio Crinò, Marcello Tiseo
Publikováno v:
The Oncologist. 24:e1165-e1171
Background Nivolumab has shown a survival benefit compared with docetaxel as second-line treatment for patients with previously treated advanced squamous non-small cell lung cancer (NSCLC) in a randomized phase III trial. The experiences of patients
Autor:
J. Goldschmidt, Keunchil Park, Filippo de Marinis, M. Gandhi, Paul Conkling, Achim Rittmeyer, Rimas V. Lukas, Joachim von Pawel, Shirish M. Gadgeel, Carol O'Hear, Marcus Ballinger, Alan Sandler, Diego Cortinovis, Sylvia Hu, Catherine Lai, Lou Fehrenbacher, Jyoti D. Patel
Publikováno v:
Lung Cancer. 128:105-112
Objectives To assess the safety and efficacy of atezolizumab and docetaxel in patients with and without a history of asymptomatic, treated brain metastases in the phase III OAK trial. Materials and methods Patients received 1200 mg atezolizumab or 75
Autor:
Maximilian Hochmair, A. Poltoratskiy, Michael Schumacher, Rafal Dziadziuszko, Silvia Novello, Konstantin Laktionov, Inna Egorova, Maria Rita Migliorino, Filippo de Marinis, W. Tang, Daphne Tsoi, Simona Rizzato, Gyula Ostoros, Antonio Passaro, L. Clementi, Agnieszka Cseh, Guzel Z Mukhametshina, Giulio Metro, Dariusz M. Kowalski, Maya Gottfried
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 152
Objectives Randomized controlled trials have demonstrated that afatinib is a suitable treatment option for patients with epidermal growth factor receptor mutation-positive (EGFRm +) non-small cell lung cancer (NSCLC). However, such studies often excl
Autor:
Filippo de Marinis, Karim Rihawi, Analia Azaro, Marzia Harnois, Alice Hervieu, Antoine Hollebecque, Gianluca Spitaleri, Corinne Gomez, Nicolas Isambert, Sylvie Assadourian, Victor Moreno, Stefania Salvagni, Katia Fiorella Dotti, Eric Angevin, Jordi Rodon
Publikováno v:
European Journal of Cancer. 87:131-139
Purpose Dysregulated MET signalling is implicated in oncogenesis. The safety and preliminary efficacy of a highly selective MET kinase inhibitor (SAR125844) was investigated in patients with advanced solid tumours and MET dysregulation. Methods This
Autor:
Alice T. Shaw, Filippo de Marinis, Ahmed Kotb, Fabrice Barlesi, Sai-Hong Ignatius Ou, Shiyao Liu, Shirish M. Gadgeel, Lucio Crinò, Ravindra Gupta, Anne-Marie C. Dingemans, Mathias Schulz, James Chih-Hsin Yang, Dong Wan Kim
Publikováno v:
British Journal of Cancer
British Journal of Cancer, 118(1), 38-42. Nature Publishing Group
British Journal of Cancer, 118(1), 38-42. Nature Publishing Group
Background: We evaluated the cumulative incidence rate (CIR) of central nervous system (CNS) and non-CNS progression in alectinib-treated patients with anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) to determine the exte
Autor:
Sabrina Giusti, Filippo de Marinis, Angelo Delmonte, Alain Gelibter, Daniele Turci, Barbara Melotti, Francesco Grossi, Paola Antonelli, Francesco Di Costanzo, Federico Cappuzzo, Stefania Canova, Lucio Crinò, Armando Santoro, Paolo Marchetti, Diana Giannarelli, Claudia Proto, Lucio Giustini, Antonio Logroscino, Teresa Gamucci, Lorenzo Livi, Alessandro Del Conte
Publikováno v:
European journal of cancer (Oxford, England : 1990). 100
This analysis evaluated the efficacy and safety of nivolumab, an immune checkpoint inhibitor, in elderly patients with stage IIIB or IV squamous non-small-cell lung cancer (NSCLC) enrolled in the expanded access programme (EAP) in Italy.Nivolumab was
Autor:
Belen San Antonio, Giorgio V. Scagliotti, Carla Visseren-Grul, Ana B Oton, Jingyi Liu, Jian Chen, Filippo de Marinis, Jean-Louis Pujol, Corey J. Langer, Cesare Gridelli, Antoinette J. Wozniak, Luis Paz-Ares
Publikováno v:
Clinical Lung Cancer
Clinical Lung Cancer, Elsevier, 2017, 18 (5), pp.489--496. ⟨10.1016/j.cllc.2017.04.003⟩
Clinical Lung Cancer, Elsevier, 2017, 18 (5), pp.489--496. ⟨10.1016/j.cllc.2017.04.003⟩
Background In a phase III study, maintenance pemetrexed showed superior survival over placebo (PARAMOUNT) for patients with advanced non-squamous non-small cell lung cancer (NSCLC) who completed 4 cycles of pemetrexed plus cisplatin (PC) induction th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba228ff49b6e7c3e6f85d91043f1a1ce
http://hdl.handle.net/2318/1680276
http://hdl.handle.net/2318/1680276
Publikováno v:
Clinical lung cancer. 15(4)
Nonhematologic toxicities are frequently observed in patients receiving epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in advanced non-small-cell lung cancer (NSCLC).For the 2010-2013 period, the authors evaluated 158 patient
Autor:
Filippo de Marinis, Kurt Banz, Christos Chouaid, Matthias Brunner, Stefan Walzer, Alain Vergnenegre, Francesco Grossi, Helge Bischoff, Javier de Castro Carpeño
Publikováno v:
Lung Cancer
Lung Cancer, 2011, 74 (3), pp.529-534. ⟨10.1016/j.lungcan.2011.04.010⟩
Lung Cancer, Elsevier, 2011, 74 (3), pp.529-534. ⟨10.1016/j.lungcan.2011.04.010⟩
Lung Cancer, 2011, 74 (3), pp.529-534. ⟨10.1016/j.lungcan.2011.04.010⟩
Lung Cancer, Elsevier, 2011, 74 (3), pp.529-534. ⟨10.1016/j.lungcan.2011.04.010⟩
International audience; Objective of this indirect economic comparison was to estimate and compare management costs of grade 3/4 adverse events (AEs) reported for first-line erlotinib or pemetrexed maintenance therapy in patients with advanced non-sm
Autor:
Johan Vansteenkiste, Radj Gervais, Jin Soo Lee, A. Makhson, Aleusandra Szczesna, Léon Bosquee, David Planchard, Joachim von Pawel, Filippo de Marinis, Paul Germonpré, Georgy M. Manikhas, Steven Gans, Kai C. Chan, Martin Reck, Giorgio V. Scagliotti, Bonne Biesma, Rodryg Ramlau, Bruno Morgan, Keunchil Park, Y. Zhu
Publikováno v:
Lung cancer: journal of the International Association for the Study of Lung Cancer
Background This is a phase II randomized study to evaluate the efficacy and safety of bortezomib and pemetrexed alone or in combination, in patients with previously treated advanced non-small-cell lung cancer (NSCLC). The primary end point was assess